Skip to content
Pharma Observatory a Scientist.com platform

Clinical trial

Phase III Randomized Trial of Taxotere/Cisplatin Followed by FOLFIRI or the Reverse Sequence in Unresectable Gastric Cancer

NCT00313872 is registered in ClinicalTrials.gov with Samsung Medical Center as lead sponsor.

NCT NCT00313872
Email me this page as a PDF

Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.

Get the NCT00313872 report as a PDF

The PDF carries up to 50 rows of each section, where the page shows the first few, with the sources listed. Enter a work email and confirm it from the message we send, and the report follows by email.

Registry record

As filed in ClinicalTrials.gov.

Title
Phase III Randomized Trial of Taxotere/Cisplatin Followed by FOLFIRI or the Reverse Sequence in Unresectable Gastric Cancer
Lead sponsor
Samsung Medical Center
Phase
Phase 3
Overall status
Completed
Start date
May 31, 2003
Completion date
January 31, 2010
Enrollment
200 (actual)
Sites
1

Conditions

As the registry lists them; a condition with its own page is linked.

gastric cancer, metastases